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A B S T R A C T
Background
Friedreich ataxia is a rare inherited autosomal recessive neurological disorder, characterised initially by unsteadiness in standing and
walking, slowly progressing to wheelchair dependency usually in the late teens or early twenties. It is associated with slurred speech,
scoliosis, and pes cavus. Heart abnormalities cause premature death in 60% of people with the disorder. There is no easily defined
clinical or biochemical marker and no known treatment. This is the second update of a review first published in 2009 and previously
updated in 2012.
Objectives
To assess the effects of pharmacological treatments for Friedreich ataxia.
Search methods
On 29 February 2016 we searched The Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, EMBASE and
CINAHL Plus. On 7 March 2016 we searched ORPHANET and TRIP. We also checked clinical trials registers for ongoing studies.
Selection criteria
We considered randomised controlled trials (RCTs) or quasi-RCTs of pharmacological treatments (including vitamins) in people with
genetically-confirmed Friedreich ataxia. The primary outcome was change in a validated Friedreich ataxia neurological score after 12
months. Secondary outcomes were changes in cardiac status as measured by magnetic resonance imaging or echocardiography, quality
of life, mild and serious adverse events, and survival. We excluded trials of duration shorter than 12 months.
Data collection and analysis
Three review authors selected trials and two review authors extracted data. We obtained missing data from the two RCTs that met our
inclusion criteria. We collected adverse event data from included studies. We used standard methodological procedures expected by
Cochrane.
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Main results
We identified more than 12 studies that used antioxidants in the treatment of Friedreich ataxia, but only two small RCTs, with a
combined total of 72 participants, both fulfilled the selection criteria for this review and published results. One of these trials compared
idebenone with placebo, the other compared high-dose versus low-dose coenzyme Q10 and vitamin E (the trialists considered the low-
dose medication to be the placebo). We identified two other completed RCTs, which remain unpublished; the interventions in these
trials were pioglitazone (40 participants) and idebenone (232 participants). Other RCTs were of insufficient duration for inclusion.
In the included studies, the primary outcome specified for the review, change in a validated Friedreich ataxia rating score, was measured
using the International Co-operative Ataxia Rating Scale (ICARS). The results did not reveal any significant difference between the
antioxidant-treated and the placebo groups (mean difference 0.79 points, 95% confidence interval -1.97 to 3.55 points; low-quality
evidence).
The published included studies did not assess the first secondary outcome, change in cardiac status as measured by magnetic resonance
imaging. Both studies reported changes in cardiac measurements assessed by echocardiogram. The ejection fraction was not measured in
the larger of the included studies (44 participants). In the smaller study (28 participants), it was normal at baseline and did not change
with treatment. End-diastolic interventricular septal thickness showed a small decrease in the smaller of the two included studies. In
the larger included study, there was no decrease, showing significant heterogeneity in the study results; our overall assessment of the
quality of evidence for this outcome was very low. Left ventricular mass (LVM) was only available for the smaller RCT, which showed
a significant decrease. The relevance of this change is unclear and the quality of evidence low.
There were no deaths related to the treatment with antioxidants. We considered the published included studies at low risk of bias in
six of seven domains assessed. One unpublished included RCT, a year-long study using idebenone (232 participants), published an
interim report in May 2010 stating that the study reached neither its primary endpoint, which was change in the ICARS score, nor a
key cardiological secondary endpoint, but data were not available for verification and analysis.
Authors’ conclusions
Low-quality evidence from two small, published, randomised controlled trials neither support nor refute an effect from antioxidants
(idebenone, or a combination of coenzyme Q10 and vitamin E) on the neurological status of people with Friedreich ataxia, measured
with a validated neurological rating scale. A large unpublished study of idebenone that reportedly failed to meet neurological or key
cardiological endpoints, and a trial of pioglitazone remain unpublished, but on publication will very likely influence quality assessments
and conclusions. A single study of idebenone provided low-quality evidence for a decrease in LVM, which is of uncertain clinical
significance but of potential importance that needs to be clarified. According to low-quality evidence, serious and non-serious adverse
events were rare in both antioxidant and placebo groups. No non-antioxidant agents have been investigated in RCTs of 12 months’
duration.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatments for Friedreich ataxia
Review question
We reviewed the evidence about the effect of antioxidants and other medicines for Friedreich ataxia.
Background
Friedreich ataxia is a rare inherited neurological condition, which first presents between 5 and 15 years of age. It initially causes
clumsiness of movement, and progresses to unsteadiness in standing and walking, with wheelchair dependency by late teens or early
twenties. Speech usually becomes slurred. A specific faulty gene must be inherited from each parent for the disease to develop in their
child (autosomal recessive inheritance). Other major problems which can develop include a curved spine (scoliosis), foot deformity
(a high arch), and heart problems, which are a cause of death in 60% of people. Friedreich ataxia has no known effective treatment.
Clinical examination and laboratory tests are not very useful for assessing disease progression, and this in turn makes interpreting
clinical trial results difficult.
Antioxidants are thought to reduce damage to cells from harmful ’free radicals’. Antioxidants occur naturally in foods in very low levels.
Recent studies have found conflicting results about the effect that the antioxidants idebenone, coenzyme Q10 and vitamin E have on
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the heart in Friedreich ataxia, as measured by thickening of the interventricular septum (the wall between two chambers of the heart),
and increased left ventricular mass (the left ventricle is the chamber of the heart that pumps blood around the body).
Study characteristics
We decided to review clinical trials that had participants who took antioxidants for at least 12 months, as Friedreich ataxia is a slowly
progressing condition. A wide search of the medical literature found four randomised controlled trials, but only two of them had
published results in medical journals. One trial, involving 28 participants, compared idebenone to a placebo. The other, involving
44 participants, compared high-dose and very low-dose combined coenzyme Q10 and vitamin E. The two unpublished trials studied
pioglitazone in 40 participants and idebenone in 232 participants, but we had no data.
Key results and quality of the evidence
According to low quality evidence from two small published trials included in the review, antioxidants did not improve neurological
symptoms in Friedreich ataxia. An additional large, unpublished study of idebenone reportedly found no benefit from idebenone for
heart or neurological symptoms, but data are not available for checking and analysis. When published this trial will very likely influence
our quality assessments and conclusions.
Although somemeasures of heart wall thickness and mass decreased in the smaller of the two published trials, the quality of this evidence
was low or very low and the importance of these findings is not clear. .
Numbers of serious or non-serious adverse events were low and similar with antioxidants and placebo. The only serious adverse event
that required withdrawal of an antioxidant was increased bowel frequency in one person receiving coenzyme Q with vitamin E.
The evidence in the review is up to date to February 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidant versus placebo for Friedreich ataxia
Patient or population: people with Friedreich ataxia
Settings: hospital outpat ients
Intervention: ant ioxidant1 versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antioxidant
Ataxia rating score
ICARS; range 0 to 100)
Follow-up: 1 year
The mean change in
ataxia rat ing score in
the control groups was
a 4.5-point decrease
and ranged f rom 0 to -
9 points2
The mean change in
ataxia rat ing score in
the intervent ion groups
was
0.79 points higher
(1.97 lower to 3.55
higher)
- 72
(2 studies)
⊕⊕©©
low3,4
Decrease in score indi-
cates improvement
Ejection fraction
Follow-up: 1 year
The mean change in
eject ion f ract ion in the
control group was a 0.
64% increase
The mean change in
eject ion f ract ion in the
intervent ion group was
0.21% lower (5.55%
lower to 5.13% higher)
- 28 (1 study) ⊕©©©
very low5
Mariott i 2003 reported
no stat ist ically signif -
icant dif f erence be-
tween treatment and
placebo groups in ejec-
t ion f ract ion. Baseline
levels were normal
End-diastolic interven-
tricular septal thick-
ness (IVSTd)
Measured in mm
Follow-up: 1 year
The mean change in
IVSTd in the control
groups was 0.47 mm
and ranged6 f rom
0.27 to -0.71 mm
The mean change in
IVSTd in the interven-
t ion groups was
-0.65 mm lower (-2.00
lower to 0.70 higher)
- 72
(2 studies)
⊕©©©
very low3,7
The clinical relevance
of the change in IVSTd
is dif f icult to interpret
(see Methods sect ion
for details)
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Left ventricular mass
(LVM )
Measured in g
Follow-up: 1 year
The mean change in
LVM in the control
group was an increase
of 16.28 g
The mean change in
LVM in the intervent ion
group was - 30.3 g (53.
34 g lower to 7.26 g
lower)
- 28 (1 study) ⊕⊕©©
low4,8
A decrease in mass
indicates improvement.
In percentage terms,
the MD was a decrease
of 16.37%(95%CI 2%to
31%) with ant ioxidant
Survival
(not measured)
- - - - - Not an outcome in ei-
ther study
Severe adverse events
Follow-up: 1 year
One event was reported
in the control groups;
the assumed risk was 3
out of 100
One event was re-
ported in the interven-
t ion groups; the risk
was
1.00, 0.07 lower to 15.
00 higher
RR 1.00 (0.07 to 15.00) 72
(2 studies)
⊕⊕©©
low9
There were 2 ad-
verse events leading
to withdrawal (placebo
group: prolonged nau-
sea; ant ioxidant group:
increased bowel f re-
quency)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; ICARS: Internat ional Cooperat ive Ataxia Rating Scale; M D: mean dif ference; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Antioxidants were idebenone and a combinat ion of coenzyme Q10 and vitamin E.
2 The assumed risk is the mean score across control groups in Cooper 2008 and Mariott i 2003.
3 We downgraded the evidence for risk of bias (study lim itat ions) and heterogeneity (imprecision).
4A large completed trial of idebenone involving 232 part icipants with Friedreich ataxia failed to reach its primary endpoint
and remains unpublished. We were unable to obtain data, rendering the results of our review at risk of publicat ion bias. As the
quality of the evidence f rom included studies is already low or very low, and the reported lack of ef f icacy in the unpublished
trial tends to support the f indings of our review, we have not further downgraded our assessments. A smaller trial (planned
enrolment 40 part icipants) invest igat ing pioglitazone is also unreported.
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5 Downgraded twice for imprecision (wide CIs in a single small study), and for the indirectness of eject ion f ract ion as a cardiac
measure in Friedreich ataxia.
6 The assumed risk is the mean score across control groupsin the two included studies.
7 We downgraded the evidence because of the high degree of heterogeneity in the analysis, and inconsistency (the 2 trials
show very dif ferent ef fects).
8 We downgraded the evidence because the outcome measure is of uncertain clinical relevance (indirectness) and the wide
CIs encompass both large and very small ef fects.
9 We downgraded the evidence twice for imprecision. CIs were very wide. There was one event in each group and the analysis
included 72 part icipants.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Friedreich ataxia (FA) is a rare inherited recessive disorder char-
acterised by a slowly progressive neurological disability, but the
most common recessively inherited ataxia worldwide. It was first
described in 1863 by the German neurologist and pathologist
Nicholas Friedreich. It has a prevalence of approximately 1 in
50,000 in European populations (Dürr 1996). It is thought that
about 50,000 individuals worldwide are affected, but more ex-
act figures are not available. There is no biomarker or easily de-
fined clinical marker for this small patient population (Di Prospero
2007; Pandolfo 2008).
Friedreich ataxia age of onset varies. It can present from early in-
fancy to adulthood with unsteadiness in standing or walking. It
is followed by progressive limb and gait ataxia, as well as slurred
speech. Most people with Friedreich ataxia are wheelchair depen-
dent by their late teens or early twenties. Cardiac dysfunction in
the form of congestive cardiac failure and arrhythmia is common.
Cardiac complications are the most common cause of death in
patients with FA (59% of deaths are from a cardiac cause (Tsou
2011)). Other significant medical problems which may develop
include scoliosis and pes cavus in 55%, diabetes in 12% to 30%
and impaired glucose tolerance in 49% of people with Friedreich
ataxia (Cnop 2012; Dürr 1996).
Mutations in theFrataxin gene (FXN) on chromosome 9q13 were
found to cause Friedreich ataxia in 1996 (Campuzano 1996).Most
people with Friedreich ataxia are homozygous for expansions of
a GAA repeat in the first intron of the FXN gene. Normal alle-
les have 40 or fewer GAA repeats while disease alleles have from
100 to more than 1700 repeats. These repeat expansions induce a
packaging of the involved genomic regions into inaccessible het-
erochromatin structure leading to gene silencing. In rare cases,
point mutations are found in heterozygosity with a GAA repeat
expansion. TheFrataxin gene encodes for a small mitochondrial
protein called frataxin, whose expression is reduced in Friedreich
ataxia (Schulz 2000).
Description of the intervention
Until 2009, the pharmacological treatments most commonly used
in clinical trials were antioxidants, of which there were many, in-
cluding pioglitazone. Since 2009, other agents have been used.
The most common drugs are deferiprone, erythropoietin, and hi-
stone deacetylase inhibitors, of which there are many, including
nicotinamide.
Antioxidants
Antioxidants are biological and chemical compounds that reduce
oxidative damage. They are a group of organic nutrients that in-
clude vitamins. The best known antioxidants are vitamins A, C,
and E, which are found in fruit, vegetables, cereals, some teas,
grape seed extract, and red wine. However, the antioxidant activity
levels in these foods do not reach what would be considered ther-
apeutic levels, capable of modifying the rate of disease progression
in Friedreich ataxia. Vitamin C increases lipo peroxidation by re-
ducing Fe3+ to Fe2+. This decreases the activity of respiratory com-
plex II. Furthermore, cellular studies have indicated that ascorbic
acid may increase some of the iron-associated adverse effects seen
in Friedreich ataxia (Rustin 1999).
The most commonly considered antioxidant medications for
Friedreich ataxia include the following.
1. Idebenone, a short chain quinone analogue that acts as a
free-radical scavenger. It is a synthetic analogue of coenzyme
Q10, a potent antioxidant and may act as an electron carrier in
the respiratory chain. It has been used in recent studies in
Friedreich ataxia.
2. Coenzyme Q10, a naturally occurring compound found in
every cell in the body. It carries electrons from complexes I and II
to complex III in the respiratory chain, playing a role in
mitochondrial adenosine triphosphate production. It is fat
soluble.
3. Vitamin E, a naturally occurring lipid soluble antioxidant.
Its deficiency causes a spinocerebellar phenotype with peripheral
neuropathy that clinically resembles Friedreich ataxia.
4. N-acetylcysteine, a precursor of glutathione, a natural
intracellular antioxidant whose protective properties have been
demonstrated in a number of cellular models. It has been used as
a treatment, for example, in liver, heart, and lung disease.
5. Selegiline, a selective monoamine oxidase B inhibitor.
Selegiline increases superoxide dismutase and catalase activity
and probably has additional antioxidant properties. It was
initially used in Parkinson’s disease for presumed neuro protective
antioxidant properties. Its clinical efficacy in Parkinsonism is
only apparent when prescribed with levo-dopa (Drugs.com).
6. Dehydroepiandrosterone, a steroid synthesised in brain glial
cells.
7. Alpha-tocopheryl quinine EPI-A0001 (A0001), a potent
antioxidant and metabolic stimulator.
8. Pioglitazone, a peroxisome proliferator-activated receptor
gamma (PPAR) molecule that is currently licensed for treatment
of diabetes mellitus. It induces the expression of enzymes
involved in mitochondrial metabolism, including superoxide
dismutase, which is an important antioxidant defence in nearly
all cells exposed to oxygen. It is proposed that this agent could be
therapeutic in neurological disease by improving the antioxidant
defence mechanism. Pioglitazone crosses the blood-brain barrier
in humans (Grommes 2013). A randomised control clinical trial
using pioglitazone in Friedreich ataxia was completed in March
2013 (NCT00811681).
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9. Some studies have used antioxidants in combination with
other pharmacological treatments (Arpa 2014).
Non antioxidant treatment
Themost commonother pharmaceuticals that have beenproposed
as treatment for Friedreich ataxia are as follows:
1. Deferiprone, an iron chelator, is a small molecule that
preferentially binds iron, a toxic metal, over other metals and
prevents a build-up of reactive oxygen species, thereby reducing
oxidative stress. Deferiprone can cross the blood-brain barrier.
2. Erythropoietin (EPO), a glycoprotein hormone produced
in the kidney that principally regulates red blood cell
production. Other biological functions include playing an
important part in the brain’s response to neuronal injury and in
the wound healing process. Recombinant human erythropoietin
(rHuEPO) was found to increase frataxin in open-label studies in
Friedreich ataxia patients (Boesch 2007; Nachbauer 2011; Saccà
2010). Recombinant DNA (rDNA) molecules are formed by
laboratory methods of genetic recombination to bring together
genetic material from multiple sources.
3. Histone deacetylase inhibitors (HDACis) modulate the
level of acetylation of chromosomal proteins and other cellular
targets, and can revert the silent heterochromatin to an active
chromatin conformation and restore the normal function of the
silenced genes (Robinson 2014). This results in a raised fraxin
level, which is the underlying problem in Friedreich ataxia
(Campuzano 1997). The HDACis used to date are nicotinamide
and 2-aminobenzamide (109/RG2833).
4. Resveratrol, a plant-derived compound that increased the
level of frataxin in cell and mouse models of Friedreich ataxia.
5. Interferon gamma-1b, a compound currently used to treat
chronic granulomatous disease and severe malignant
osteopetrosis (BNF 2016).
How the intervention might work
Antioxidants are postulated to protect against oxidative stress in
neuronal and cardiomyocytes, which is caused by a loss of frataxin
in Friedreich ataxia. Frataxin is ubiquitous, with high levels in
the central and peripheral nervous systems and in some non-neu-
ronal tissues, such as the heart, pancreas, liver, muscle, thymus,
and brown fat. Some, but not all, of these tissues are affected in
Friedreich ataxia; for example, in the nervous system, primary sen-
sory neurons, the dentate nucleus, and pyramidal tracts undergo
atrophy, while other neuronal systems are much more resistant,
despite similar levels of frataxin expression.
When frataxin is deficient, the mitochondrial function of the cell
is severely affected. There is a loss of iron sulphur proteins, res-
piratory chain I, II, III complexes, and aconitase. This causes a
reduction in adenosine triphosphate generation. This reduction
was confirmed using magnetic resonance spectroscopy on cardiac
muscle (Lodi 2001). Mitochondria also become overloaded with
iron. This causes an increase in reactive oxygen species which has
been verified by increased levels of plasma malondialdehyde and
urinary 8-hyroxy-2-deoxyguanosine (Emond 2000). Both respi-
ratory chain dysfunction and oxidative stress are likely to result in
cardiac or cardiomyocyte hypertrophy and neuronal cell dysfunc-
tion. Antioxidants are postulated to protect against these effects.
Deferiprone is proposed to work in Friedreich ataxia by redis-
tributing iron from the overloaded mitochondrial compartment
to the cytosol (Kakhlon 2008). Using regimens suitable for pa-
tients with no iron overload, deferiprone has been associated with
an imaging reduction of iron signal in the dentate nuclei of people
with Friedreich ataxia as well as a reduction in neuropathy and
ataxia in one open study (Boddaert 2007). Deferiprone does not
cause overall iron depletion, unlike other iron chelators, and this
makes it an interesting candidate for Friedreich ataxia treatment
(Pandolfo 2014).
Erythropoetin, in the form of recombinant human erythropoietin
(rhuEPO), has been shown in open label studies to significantly
increase frataxin expression in many cells, including lymphocytes
from Friedriech ataxia patients in vitro (Boesch 2007; Nachbauer
2011; Saccà 2010).
Histone deacetylase inhibitors (HDACis) work by raising the
frataxin level. Herman 2006 showed that in human lymphoblas-
toid cells from Friedreich ataxia patients, it was possible to revert
the FXN gene silencing and raise the low frataxin level. A report
from the 2014 Annual American Neurology meeting further con-
firmed that HDACis induce increased expression of frataxin gene
in the participants (Robinson 2014).
Interferon gamma-1b has been found to increase frataxin expres-
sion in dorsal root ganglion neurons in treated mouse models
and these models also had improved sensorimotor performance
(Tomassini 2012).
Why it is important to do this review
Currently, there is conflicting evidence about the value of differ-
ent treatments in Friedreich ataxia, and in particular, the value of
antioxidants. Clinical trials using antioxidants in Friedreich ataxia
have been ongoing since the late 1990s and have suggested that
idebenone, an antioxidant, may help left ventricular hypertro-
phy, the most frequent heart abnormality (Buyse 2003; Hausse
2002; Mariotti 2003; Pineda 2008; Ribai 2007; Rustin 1999).
However, Ribai 2007 found that even though left ventricular
mass improved, cardiac function, asmeasured by ejection fraction,
did not improve. Artuch 2002 and Lynch 2010 did not demon-
strate an improvement in cardiac measures with idebenone. Schulz
2000 treated 48 people with Friedreich ataxia with the antioxi-
dant idebenone over an eight-week period and found a significant
decrease in urinary 8-hydroxy-2-deoxyguanosine. A more recent
study assessed 48 participants over six months and did not observe
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significant changes in the concentrations of urinary 8-hydroxy-2-
deoxyguanosine after idebenone treatment (Di Prospero 2007).
Quebec licensed the antioxidant idebenone from July 2008 for
the treatment of Friedreich ataxia. Initial licensing was conditional
upon the outcome of clinical trials (Health Canada 2009). Dur-
ing that period, idebenone was provided free of charge, but Que-
bec withdrew the licence in April 2013. In November 2008, the
European Medicines Agency refused marketing authorisation for
idebenone in Europe (EMA 2009). The US Food and Drugs Ad-
ministration has never authorised idebenone for use in Friedreich
ataxia.
This is the second update of a review first published in 2009 and
previously updated in 2012 (Kearney 2009; Kearney 2012).
O B J E C T I V E S
To assess the effects of antioxidants and other pharmacological
treatments for Friedreich ataxia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) or quasi-RCTs of antioxi-
dants and other pharmacological treatments for Friedreich ataxia.
Quasi-RCTs are studies that use semi-systematic methods of al-
location to treatments, for example, alternation, or allocation by
case record number of date of birth.
Types of participants
Participants with genetically-confirmed Friedreich ataxia at all
stages of their illness, both sexes, and any age.
Types of interventions
Any pharmacological treatment compared with any other phar-
macological treatment, placebo, or no treatment.We included any
form of treatment considered to have an antioxidant effect (in-
cluding vitamins) as well as other pharmacological treatments.
We analysed antioxidants as a group. We would have performed
additional subgroup analyses of individual antioxidants if the re-
view had included sufficient trials. We would have considered
other pharmacological treatments individually, or within thera-
peutic groups, as appropriate.
Types of outcome measures
Primary outcomes
Change in score on validated Friedreich ataxia rating scales after
12 months of treatment. We considered the following scales:
• Scale for the Assessment and Rating of Ataxia (SARA);
• Friedreich Ataxia Rating Scale (FARS);
• International Cooperative Ataxia Rating Scale (ICARS).
An absolute reduction in these scores indicates improvement.
Friedreich ataxia is a slowly progressive disorder. There is no bio-
chemical or simple clinical measure of progression. Current scor-
ing systems are composite scores of disability and impairmentmea-
sures: the ataxia rating scales. The SARA, which is primarily, but
not exclusively, an impairment scale, has been validated for both
spinocerebellar ataxia and Friedreich ataxia (Bürk 2009), and is
the preferred scale in the most recent trials. The FARS was vali-
dated in 2006 (Fahey 2006). The ICARS was developed for neu-
rological conditions by a committee of the World Federation of
Neurology in 1997 and was validated (Trouillas 1997). In future,
pure disability or impairment scales would be preferable as pri-
mary outcome measures in the review. If these are used in trials,
currently reported mixed scales will become secondary outcome
measures.
Secondary outcomes
Wealso assessed secondary outcomes after 12months of treatment.
1. Change in cardiac measures: ejection fraction, end-diastolic
interventricular septal thickness (IVSTd) and left ventricular
mass (LVM), as measured by cardiac magnetic resonance
imaging (cMRI).
2. Change in cardiac measures: ejection fraction, end-diastolic
IVSTd, LVM as measured by echocardiogram.
3. Improvement in any validated quality of life score.
4. Mild adverse effects (medication continued).
5. Severe adverse affects (defined as leading to cessation of
medication).
6. Survival.
There has been much debate about how best to quantify the car-
diomyopathy in Friedreich ataxia. Weidemann 2012 reviewed the
cardiac status of 205 people with Friedreich ataxia in detail. The
study found that IVSTd, as measured by echocardiogram, was a
reliable predictor of LVM when the results were correlated with
those from cMRI. The latter has been shown to be the more sensi-
tive and accurate in determining the severity of cardiomyopathy in
Friedreich ataxia (Grothues 2002). Cardiac assessment is compli-
cated, as there is not a single cut-off point for defining normal ver-
sus abnormal IVSTd in this group of people. The clinical pheno-
type varies, disease progression is variable, and with the passage of
time, people with Friedreich ataxia develop a worsening cardiomy-
opathy. People with Friedreich ataxia commonly develop myocar-
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dial fibrosis with a subsequent decrease in IVSTd, which could be
mistaken for a positive treatment effect (Weidemann 2012).
An ejection fraction of 55% or higher is considered normal (Mayo
Clinic 2015). For this review, we selected ejection fraction as the
principal criterion for defining the severity of cardiomyopathy and
measuring heart function in Friedreich ataxia (Weidemann 2012),
in conjunction with IVSTd.
Search methods for identification of studies
Electronic searches
We searched The Cochrane Neuromuscular Specialised Regis-
ter (29 February 2016), CENTRAL (29 February 2016 in the
Cochrane Register of Controlled Trials Online (CRSO)), MED-
LINE (January 1966 to February 2016), EMBASE (January 1980
to February 2016), CINAHL Plus (January 1937 to February
2016),ORPHANET (1990 to September 2015), andTRIP (1998
to September 2015).
We have presented the detailed search strategies in the appendices:
Appendix 1 (Cochrane Neuromuscular Specialised Register),
Appendix 2 (CENTRAL), Appendix 3 (MEDLINE), Appendix
4 (EMBASE), Appendix 5 (CINAHL Plus), Appendix 6 (OR-
PHANET) and Appendix 7 (TRIP).
We decided in advance that if we included clinical trials conducted
prior to 1996 (genetic diagnosis of Friedreich ataxia became avail-
able in 1996), we would exclude their results from further analysis
if genetic confirmation had not been subsequently carried out.
As searching AMED, LILACS and PEDRO produced no useful
results, we did not search these databases after the first version of
this review.
Searching other resources
Three review authors inspected the reference lists of all papers
selected from the searches.We performed a search of the references
listed in the published studies, reviews, and relevant conference
proceedings. We also considered studies in languages other than
English for inclusion. We consulted the Clinical Trials Registry of
the U.S. National Institute of Health (Clinical trials) to identify
additional trials that had not yet been published. We searched the
World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/) (last searchMarch 2016).We
obtained the latest results from the RCTs by searching conference
proceedings, canvassing colleagues, and reviewing the websites of
the patient organisations, Friedreich Ataxia Research Alliance and
euro-ataxia.
Data collection and analysis
We conducted data collection and analysis in accordance with
the Cochrane Handbook for Systematic Reviews of Intervention (
Higgins 2011). Figure 1 shows the flow of information through
the different phases of the systematic review.
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Figure 1. A flow diagram illustrating the study selection process.
Selection of studies
Three review authors (MK, RO, and MF) independently checked
titles and abstracts obtained from literature searches to identify
potentially relevant trials for the review. They obtained the full text
of all potentially relevant studies for independent assessment. The
review authors resolved disagreements about inclusion criteria by
discussion.
Data extraction and management
Two authors (MK and RO) independently extracted data from the
included studies onto a specially designed data extraction form.
They resolved disagreements by discussion. Review authors sought
further data from the lead author of Cooper 2008, as the study
report provided outcome data at two years rather than at one year
as specified in our protocol.
Assessment of risk of bias in included studies
We assessed risk of bias in the included studies using the Cochrane
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‘Risk of bias’ tool, considering the domains of random sequence
generation, allocation concealment, blinding (investigators, par-
ticipants, and outcome assessors), incomplete outcome data, se-
lective outcome reporting and other sources of bias. We made a
judgment on each of these criteria, rating studies as at ‘High risk
of bias’, ‘Low risk of bias’ or ‘Unclear risk of bias’ for each criterion
(Figure 2).
Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study. We could not evaluate attrition bias in the unpublished studies.
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Measures of treatment effect
We reported risk ratios (RRs) with 95% confidence intervals (CIs)
for binary outcomes such as adverse events. For continuous out-
comes, such as ICARS scores, ejection fraction, IVSTd, and LVM,
we calculated mean differences with 95%CI. If trials had reported
the same outcome using different measurement tools, we would
have combined data using standardised mean differences and 95%
CIs.
We analysed all the primary and secondary outcomes under con-
sideration whenever the data allowed.
Unit of analysis issues
The unit of analysis was a participant. To prevent unit-of-analysis
issues related to repeated measures, we chose to analyse outcome
data after 12 months of treatment.
Dealing with missing data
Since completion of the previous review update in 2012, Dr
Cooper provided raw data on the change in the ICARS score and
IVSTd after 12 months (Cooper 2008). We completed the data
extraction form and determined that we could include this study
in this updated review.
We sought details of the primary outcome of Mariotti 2003 from
Dr Mariotti in 2009, who supplied the mean, standard deviation
and P value for ICARS scores at the start and after 12 months
for both the placebo and the treatment groups. We included these
details on the data extraction sheet for the initial publication of
this review in 2009. We sought details of ejection fraction mea-
surements for the 2015 update and the raw data on these mea-
surements were supplied.
Weidemann 2012 was completed in 2009, We contacted the tri-
alists several times, and on our last contact in January 2016, the
lead investigator, Dr Frank Weideman, responded to our query,
advising that the manuscript was in preparation.
We contacted the authors of NCT00811681 in January 2016. Dr
Pierre Rustin responded by email, and told us that the clinical trial
had missed its primary endpoint, change in neurological score.
Assessment of heterogeneity
We used the I2 test for heterogeneity. We considered that an I2
greater than 50% suggested that variations in the effect estimates
of the different studies were due to differences between trials rather
than to chance alone. We initially used a fixed-effect model and
repeated the analysis with a random-effects model.
Assessment of reporting biases
The search strategies coveredmultiple sources without language or
publication restrictions. We were alert to the possibility of dupli-
cation of studies. We did not produce a funnel plot, as the review
included too few studies for an analysis of small study effects to
be meaningful (Sterne 2011).
Data synthesis
We performed statistical analyses of the data using Review Man-
ager 5 (RevMan 5). We combined data from primary studies of
antioxidants versus placebo and reported the results of analyses
using a random-effects model.
‘Summary of findings’ table
We created a ‘Summary of findings’ table for each comparison
using the following outcomes: change in ICARS score, change in
cardiac measures (ejection fraction, IVSTd, and LVM), severe ad-
verse events, and survival.Weused the fiveGRADEconsiderations
(study limitations, consistency of effect, imprecision, indirectness,
and publication bias) to assess the quality of a body of evidence
(studies that contribute data for the prespecified outcomes). We
used methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using GRADEpro software. We jus-
tified all decisions to downgrade or up-grade the quality of studies
using footnotes, and we made comments to aid readers’ under-
standing of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was not relevant.We investigated heterogeneity
by inspecting trials and the forest plot. We reviewed the clinical
and methodological characteristics of the included studies.
Sensitivity analysis
Sensitivity analysis was not relevant.
R E S U L T S
Description of studies
Results of the search
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The numbers of papers found by the update searches run by the
Cochrane Neuromuscular Information Specialist were: Cochrane
Neuromuscular Specialised Register = 34, CENTRAL = 24,
MEDLINE = 64, EMBASE = 41, CINAHL Plus = 33, DARE =
6, HTA = 1, for a total of 203 new records (181 after deduplica-
tion). The review authors identified 135 new records in TRIP, 1
new record in ORPHANET, and 79 additional records through
searching other sources. The review authors identified eight stud-
ies (reported in nine full-text articles) to be studied in detail for
eligibility (see PRISMA flow chart Figure 1). From these, we iden-
tified no new studies through the searches for this update. To the
one study included in the last version of this review, we added three
other studies previously identified as either awaiting classification
or ongoing.
Included studies
In the initial review and first update, we included one study
(Mariotti 2003), and one other study awaited classification
(Cooper 2008). As a result of information from the trial author, we
included Cooper 2008 in this update of the review. We reviewed
the information on Weidemann 2012 and NCT00811681 and
found that they also met our selection criteria.
Cooper 2008 initially included 50 participants with genetically-
confirmed homozygous expansion for Friedreich ataxia. The trial
compared high-dose and a very low-dose of coenzyme Q10 and
vitamin E antioxidants over a two-year period. The trial authors
considered the very low dose coenzyme Q10 and very low dose
vitaminE as placebos. The authors justified this, citing recruitment
difficulties for a trial involving a placebo group.
Mariotti 2003 compared the antioxidant idebenone 5 mg/kg to
placebo in 29 participants with genetically-confirmed homozy-
gous expansion for Friedreich ataxia. In all participants, the con-
dition had been present for over 10 years. Eighteen participants
were wheelchair dependent at the onset of the study.
InWeidemann 2012, 232 participants were randomised to receive
idebenone or placebo (dosage adjusted for weight) and 205 pro-
vided outcome data. At the planning stage of this study, the trialists
decided to enrol a significant number of ambulatory participants,
as defined by a person who could walk at least 10 meters with or
without a walking aid but without the help of an accompanying
person.
NCT00811681 was a double-blind clinical trial of pioglitazone
over a two-year period, involving 40 participants with confirmed
Freidreich ataxia. The pioglitazone dose was increased to a maxi-
mum of 45mg/day and the primary endpoint was change in ataxia
rating scale score (ICARS) after two years. The study was com-
pleted in March 2013 but to date, remains unpublished.
Both published trial reports provided details of funding sources.
Cooper 2008 was funded by Ataxia UK, the Wellcome Trust,
and the Medical Research Council in the UK, and Pharma Nord
supplied the medication. Mariotti 2003 was funded by the Italian
Ministry ofHealth, andTakeda-Italy supplied the trialmedication.
See Characteristics of included studies.
Excluded studies
There were five excluded studies, described in six reports (two of
the reports were from the same study (Lynch 2010)).We excluded
these trials because they did not fulfil the duration criterion of 12
months. See Characteristics of excluded studies.
Di Prospero 2007 was a six-month, open-label, dose-escalation
trial of idebenone involving 48 people (9 to 17 years) with ge-
netically-confirmed Friedreich ataxia. Participants received 5 mg/
kg, 15 mg/kg, or 45 mg/kg idebenone, or placebo. Outcomes
were change in a urinary marker of oxidative DNA damage, 8-
hydroxy-2’-deoxyguanosine, and changes from baseline in ICARS
and FARS scores, and in activities of daily living,
In Lynch 2010, 70 ambulant participants with genetically-con-
firmed Friedreich ataxia (aged 8 to 18 years) were enrolled in a
six-month double-blind, parallel-group RCT. The trial compared
two different doses of idebenone (450 mg/day or 900 mg/day for
body weight less than 45 kg; 1350 mg/day or 2250 mg/day for
body weight greater than 45 mg/kg), and placebo. The primary
outcome was the ICARS score; FARS, Friedreich’s Ataxia Com-
posite Test (FACT-Z3), and activities of daily living scores were
secondary outcomes.
Pandolfo 2014 was a six-month double-blind RCT in which 72
participants (7 to 35 years of age) with genetically-confirmed
Friedreich ataxia received deferiprone (20 mg/kg/day, 40 mg/kg/
day, or 60 mg/kg/day) or placebo, divided into two daily doses.
The main aim of the study was to determine safety and tolerabil-
ity. Changes in 9-hole peg test, timed 25-foot walk, low-contrast
letter acuity, ICARS, and FARS scores were secondary outcomes.
Cardiac measures and activities of daily living were also assessed.
Mariotti 2010 was a randomised, double-blind, placebo-con-
trolled, dose-finding trial. Sixteen adults with Friedreich ataxia
received erythropoietin in three consecutive cycles intravenously
(20,000 to 40,000 units every two weeks) or placebo over a six-
month period, followed by a six-month phase of subcutaneous
treatment. All patients were also treated with idebenone (5mg/kg/
day). The study assessed safety and frataxin levels in lymphocytes.
Schöls 2005 was a randomised, placebo-controlled, cross-over
study comparing L-carnitine (3 g daily), creatine (6.75 g daily)
and placebo over a four-month period. Participants were 16 ambu-
lant adults with genetically-confirmed Friedreich ataxia. The tri-
alists assessed “mitochondrial ATP production measured as phos-
phocreatine recovery by 31Phosphorus magnetic resonance spec-
troscopy,” ICARS scores, and cardiac hypertrophy by echocardio-
graphy.
Studies awaiting classification
There are no studies awaiting classification.
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Ongoing studies
None of the several ongoing studies in Friedreich ataxia fulfil the
selection criteria set by this review as being an RCT of at least one
year’s duration.
Risk of bias in included studies
The review authors’ ‘Risk of bias’ judgements for the included
studies are summarised in Figure 2. See Characteristics of included
studies for detailed assessments of each study.
Allocation
The two included published studies provided sufficient detail of
the randomisationof participants to consider themprobably at low
risk of bias from sequence generation and allocation concealment.
Blinding
Cooper 2008 reported that participants were blinded until the end
of the trial and that the placebo medication was indistinguishable
from the active medication. The Mariotti 2003 manuscript did
not mention whether participants were blinded but the contact
author stated in an email that the assessors of the primary and
secondary outcomes were blind to the participants’ assignment.
Incomplete outcome data
In the Cooper 2008 study, six of the original 50 participants with-
drew, three from high dose group and three from the low dose
group. In the Mariotti 2003 study one participant withdrew from
the placebo group.
Selective reporting
Trial protocols were unavailable for Cooper 2008 and Mariotti
2003, therefore, it is not possible on the basis of the published
reports alone to determine whether all expected outcomes were
reported. For each trial, investigators provided raw data for the
outcomes of interest in the review.The unpublished but completed
study Weidemann 2012 represented a high risk of reporting bias.
We assessed NCT00811681 as unclear.
Other potential sources of bias
In Mariotti 2003, the proportion of ambulant versus wheelchair-
dependent participants was different in the intervention and
placebo groups. Cooper 2008 did not provide this information.
In Cooper 2008, the authors reported no conflict of interest.
Mariotti 2003 made no reference to conflicts of interest.
Effects of interventions
See: Summary of findings for themain comparisonAntioxidant
versus placebo for Friedreich ataxia
Antioxidants versus placebo
Outcome data were not available for Weidemann 2012 or
NCT00811681, which were unpublished trials.
Primary outcome measure: change in ataxia rating scale
after 12 months
Changes in the ataxia rating scales SARA or FARS after 12months
treatment were not measured in either Cooper 2008 or Mariotti
2003.
Data for the change in ICARS scores were available for two studies
(Cooper 2008; Mariotti 2003). The ICARS score ranges from 0
to 100, with higher scores indicating greater severity.
In the published studies, the scores did not reveal any signifi-
cant difference between the antioxidant and placebo groups at 12
months. The individual participant ICARS scores before and af-
ter treatment were provided for Cooper 2008, after contact with
the author. These scores were not available for Mariotti 2003, for
which the trial author supplied the mean change in ICARS scores
for each group, but not the change in score for each participant.
We estimated the within-group SD for Mariotti 2003 using the
observed correlation in the Cooper study (using rho = 0.94). The
MD for the change from baseline in the ICARS for antioxidant
versus placebo in Cooper 2008 was -0.64 (95% CI -3.66 to 2.38).
Mariotti 2003 reported a 9-point decrease in the ICARS score
from baseline to 12 months in the placebo group and a 0.8 point
decrease in the antioxidant group. TheMD for change from base-
line to 12 months in Mariotti 2003 was 8.20 (95% CI 1.35 to
15.05). Pooling data from the two trials, the MDwas 0.79 points,
95% CI -1.97 to 3.55 (N = 72). We considered the evidence as
low quality, downgrading for heterogeneity (Chi² = 5.36, df = 1
(P = 0.02); I² = 81%) (Analysis 1.1 and Summary of findings for
the main comparison).
Changes in ICARS and FARS scores from baseline to week 52
were both outcomes in Weidemann 2012. The study sponsors,
Santhera, reported in a press release that “the primary endpoint of
the study, mean change in the International Cooperative Ataxia
Rating Scale (ICARS) score from baseline, did not detect any sig-
nificant difference between the active dose arms and placebo” and
secondary endpoints “including the proportion of patients im-
proving on ICARS score (responder analysis) and change in the
Friedreich’s Ataxia Rating Scale also did not show statistically sig-
nificant differences between the placebo and active dose groups”.
These statements are consistent with the findings from included
studies, but data were not available to the review authors for in-
dependent analysis.
NCT00811681 measured the change in ataxia rating scales as
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measured by ICARS and FARS every six months over a two-year
period. We were unable to obtain data for analysis.
Secondary outcome measures: change in cardiac measure
Change in cardiac status using cMRI was not measured in Cooper
2008 orMariotti 2003, but both studies assessed change in cardiac
status using echocardiogram.
Change in ejection fraction
Ejection fraction data were only available for Mariotti 2003.
None of the participants in Mariotti 2003 had “pathologic ejec-
tion fraction at baseline”, as the ejection fraction remained above
50% in all trial participants over the year of follow-up. Ejection
fraction increased by 0.64% in the placebo group and 0.43% in
the antioxidant group, a mean difference (MD) of -0.21% (95%
CI -5.55 to 5.13) (Analysis 1.2). We assessed the quality of the
evidence as very low. Cooper 2008 measured fractional shortening
at 12 months rather than ejection fraction; the latter is considered
to be a more accurate reflection of heart function (Mayo Clinic
2015). We were unable to obtain fractional shortening data for
Cooper 2008.
Change in interventricular septal thickness as measured by
echocardiography
Cooper 2008 and Mariotti 2003 measured change in IVSTd, in
which a decrease indicates improvement. The scores revealed a
small difference between the antioxidant treated groups and the
placebo groups at 12 months in favour of idebenone in Mariotti
2003. InCooper 2008, therewas no improvement. TheMD(mm)
of the combined measures was -0.65 (95% CI -2.00 to 0.70, N =
72, random-effects) in favour of antioxidant treatment (Analysis
1.3). We considered this evidence as very low quality because of
risk of bias, marked statistical heterogeneity (I2 statistic = 74%),
and inconsistency (one trial shows a strong effect, the other none)
(Analysis 1.3; Summary of findings for themain comparison). The
CIs are wide, including both the possibility of change that might
be clinically important and no effect.
Change in left ventricular mass
Results for left ventricularmass were available fromMariotti 2003.
Left ventricular mass increased by 16.28 g (SD 29.37) in the
placebo group and decreased by 14 g (SD 32.75) in the antiox-
idant group (MD -30.30 g, 95% CI -53.34 to -7.26, in favour
of the antioxidant) (Analysis 1.4). There was a 10.7% (P = 0.01)
increase in left ventricular mass after 12 months of treatment in
the placebo group and a 5.6% decrease in the idebenone-treated
group after 12 months of treatment. The MD was 16.37% (95%
CI 2% to 31%). The potential importance of these results needs
to be clarified in view of the fact that people with Friedreich ataxia
commonly developmyocardial fibrosis with a subsequent decrease
in LVM, which could be mistaken for a positive treatment effect.
The press release reporting the failure of Weidemann 2012 to
reach its endpoints reported “no difference between the active
and placebo groups in the key cardiological secondary endpoint
assessing a combination of anatomical and functional cardiac
parameters”. We were unable to obtain data for analysis. See
Characteristics of included studies for details of cardiac measures
listed in the trial registry entry.
Cardiac outcomes in NCT00811681 were not fully described in
the clinical trials registry entry.
Improvement in quality of life score after 12 months
Not assessed by Cooper 2008 or Mariotti 2003.
Change in quality of life scale measured by the Short Form 36
(SF-36) score after 12 months of treatment was among the listed
outcomes in NCT00811681. No data were available.
Mild adverse effects
In Cooper 2008, the authors reported the intervention to be well
tolerated and provided details of withdrawals, but did not specif-
ically report the occurrence of mild adverse events. In Mariotti
2003, one participant experienced occasional tachycardia, which
did not require treatment modification (Analysis 1.5).
Severe adverse effects
In Cooper 2008, one participant in the placebo group withdrew
due to prolonged nausea, and one participant in the treatment
group withdrew due to increased bowel frequency. In Mariotti
2003, there were no severe adverse effects due to idebenone or
placebo.
One of the placebo participants in Mariotti 2003 died during
the study as a result of diabetic ketoacidosis five months after
enrolment. The trial authors considered the death to be unrelated
to the clinical trial.
Survival
Survival was not an outcome in the included studies.
D I S C U S S I O N
Summary of main results
Effectiveness of pharmacological treatments versus
placebo
16Pharmacological treatments for Friedreich ataxia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Neither of the published included studies showed that antioxidants
were effective for treating Friedreich ataxia using the primary out-
come, change in the validated Friedreich ataxia neurological scale,
International Cooperative Ataxia Rating Scale (ICARS; Cooper
2008;Mariotti 2003). The included studies showed contradictory
evidence in the secondary outcome, change in interventricular sep-
tal thickness as measured by echocardiography. Mariotti 2003 (28
participants) did show a significant change in left ventricular mass
(LVM). This is of uncertain clinical significance, but of potential
importance that needs to be clarified.
Among the secondary cardiac outcomes, change in ejection frac-
tion using echocardiogram was not measured in the Cooper 2008
study. Ejection fraction was measured in Mariotti 2003, but was
normal at the outset of the study, so was not likely to demonstrate
change after 12 months’ treatment. Results confirmed this.
Both reported studies measured change in end-diastolic interven-
tricular septal thickness (IVSTd). There was no improvement in
IVSTd in Cooper 2008. In Mariotti 2003, it showed a small im-
provement in favour of the antioxidant group. When we reviewed
this result, we considered that in the absence of any improvement
in ejection fraction, the improvement in IVSTd was of no clear
clinical significance, although the result was too imprecise to rule
out the possibility of an effect.
We were not successful in our attempts to obtain data from two
unpublished studies, which involved a combined total of approx-
imately 272 participants.
Overall completeness and applicability of
evidence
The low- or very low-quality evidence in this review is cur-
rently insufficient to support or refute an effect of antioxidants
in Friedreich ataxia. The authors felt that all relevant studies were
identified but the evidence is incomplete, as Weidemann 2012
and NCT00811681 had no published results as of May 2016.
Santhera, the sponsors of Weidemann 2012, published an in-
terim report in May 2010 stating that the study had failed to
reach its primary endpoint, which was change in ICARS score
(Santhera 2010). The company also reported no change in sec-
ondary endpoints Friedreich Ataxia Rating Score (FARS), and car-
diac parameters. The results of these unpublished trials, partic-
ularly Weidemann 2012, which involved 232 participants with
Friedreich ataxia, represent important missing data.
For years, idebenone was available to some people with Friedre-
ich ataxia free of charge, while others had to pay for it. After
the European Medicines Agency refused marketing authorisation
for idebenone, several European countries and some private in-
surance companies reviewed their policies on reimbursement and
no longer supply this medication to people with Friedreich ataxia
(EMA 2009). The evidence seems to suggest that idebenone is not
effective, and this is supported rather than refuted by the unpub-
lished study (Weidemann 2012).
We identified no trials of non-antioxidant agents eligible for in-
clusion in the review.
Evidence from excluded studies
We limited this review to studies at least a year long, as shorter
studies in this slowly progressive condition are unlikely to demon-
strate clinical benefit. As this potentially excludes short-term trials
signalling clinical efficacy, we briefly described excluded studies
here as they have helped considerably to add to the body of knowl-
edge about clinical trials in Friedreich ataxia.
Di Prospero 2007 was a six-month, open-label dose-escalation
trial involving 48 people with genetically-confirmed Friedreich
ataxia. Higher doses of idebenone led to a proportional increase in
plasma levels and were well tolerated. One child on a high dose of
idebenone experienced neutropenia, which recovered when treat-
ment was stopped. Overall, ICARS, FARS, and total activity of
daily living (ADL) scores did not improve with idebenone. Im-
provement in ICARS scores but not FARS or ADL scores showed
dose dependence and the difference from placebo was statistically
significant at the higher doses. The subgroup of ambulant but
symptomatic participants (baseline ICARS scoremore than 10 but
less than 54), showed improvement in ICARS but not in FARS
or ADL scores.
Lynch 2010 reported that idebenone did not alter neurological
function in Friedreich ataxia after six months of treatment. It
also demonstrated that the sensitivity of the ataxia rating scales to
change is limited, and suggested that in future studies, inclusion
of a higher percentage of ambulant participants would be desir-
able. Idebenone did not decrease left ventricular hypertrophy or
improve heart function in this study.
Recombinant human erythropoietin (rHuEPO) was used in two
RCTs, which found acceptable safety and tolerability of rHuEPO
derivatives in Friedreich ataxia, but did not find any increase in
frataxin levels or improvement in the clinical condition of partici-
pants over a two-week RCT (Boesch 2014), or over the six-month
period in Mariotti 2010.
There is rationale for deferiprone as a therapy for Friedreich ataxia;
however, its safety and appropriate dosing need to be assessed
prior to another large scale trial. Pandolfo 2014 was a six-month
study involving 74 randomised adults and children with Friedre-
ich ataxia. A dose of 20 mg/kg/day was well tolerated, whereas
40 mg/kg/day produced a worsening of ataxia scores (ICARS and
FARS). The highest dose, 60 mg/kg/day dose was discontinued as
a precautionary measure, because two participants experienced a
worsening of ataxia. Ataxia in the placebo group did not deterio-
rate over the six-month period and this prevented the researchers
from detecting any potential protective effect of deferiprone. Left
ventricular mass decreased in treatment versus placebo arms, but
the clinical significance of this is unclear. The trial produced in-
conclusive efficacy results, with no improvement over placebo at
20 mg/day, but it was too short to rule out an effect. Based on
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subgroup analyses, the trial authors considered that lower doses
warranted further investigation.
A cross-over trial comparing L-carnitine (3 g daily in three doses),
creatine (6.75 g daily in three doses), and placebo over a four-
month period among 16 ambulant adults with genetically-con-
firmed Friedreich ataxia, found that neither echocardiographic
data nor ICARS scores demonstrated an improvement over base-
line or placebo (Schöls 2005).
Evidence from other studies
A histone deacetylase inhibitor (HDACi),109/RG 2833 was well-
tolerated in a phase 1 trial (Soragni 2014), but Robinson 2014 re-
ported that two drug metabolites persisted in the serum for hours
after the compoundwas broken down, one a suspected cardiotoxin
and the other a suspected carcinogen. This led the group to be-
gin developing related compounds that penetrate the blood-brain
barrier but which are without these effects. Libri 2014 used the
HDACi nicotinamide in an open-label, dose-escalation study over
an eight-week period. This study showed a sustained improvement
in frataxin concentration over the course of the treatment.
Gene therapy research in Friedreich ataxia has been ongoing for
the last 10 years. A GAA-expanded frataxin genomic DNA re-
portermodel of Friedreich ataxia has been developed. whichwould
lead the way to identification of novel therapies (Lufino 2013).
In Friedreich ataxia, protection for nerve cells would be a priority.
Kemp 2011 looked to see if bone marrow-derived cells might be
able to protect cerebellar neurons in vitro. He demonstrated “that
normal human mesenchymal stem cells (MSCs) induce both an
increase in frataxin gene and protein expression in Friedreich ataxia
fibroblasts via secretion of soluble factors”. The most recent study,
Perdomini 2014, reported that cardiomyocytes from mice with
severe energy failure and ultra structural disorganisation, can be
rapidly rescued and remodelled by gene therapy. This established
pre-clinical proof of concept for the potential of gene therapy in
treating Friedreich ataxia cardiomyopathy.
Many of the studies referenced in this section have been based at
multiple centres in different countries and continents. In recent
years, clinicians have been keen to organise double-blind clinical
trials. Patient organisations have come together internationally to
make patient recruitment for clinical trials possible.
Quality of the evidence
The quality of the evidence from the results of the two included
and reported studies was low for the validated Friedreich ataxia
neurological scale score, ICARS, and low or very low for other
outcomes. As Friedreich ataxia varies considerably in genetic sever-
ity, has a varying age of onset from 5 to 60 years, has a variable
clinical progression, and is heterogeneous in its clinical features,
much of the recent research has focused on finding an accurate
measure of disease progression (Bürk 2009). Lynch 2010 revealed
that the sensitivity of the neurological examination when using
the ICARS and the FARS was limited, and each scale had a variety
of other drawbacks. When the participants are wheelchair-depen-
dent, posture and gait scores in the ICARS are redundant, leading
to a sudden, significant deterioration in the person’s ICARS score
when they become wheelchair-dependent, followed by a period
where there is almost no change in the score, which is know as a
ceiling effect. In the planning stage of Weidemann 2012, an ef-
fort was made to eliminate this ceiling effect by enrolling a sig-
nificant percentage of ambulatory participants. Weidemann 2012
reported that 51.8% of participants were ambulatory. In Mariotti
2003, 37% were ambulatory, that is, 11 out of 29 participants.
A collaborative project funded by the European Commission,
called the European Friedreich’s Ataxia Consortium for Transla-
tional Studies (EFACTS; www.e-facts.eu), is testing the validity
of ataxia rating scales in a four-year prospective study from 2012
to 2016. It reviews its Friedreich ataxia participants on an annual
basis. An American network, Collaborative Clinical ResearchNet-
work in Friedreich Ataxia (CCRN in FA; www.curefa.org), is test-
ing the validity of the FARS for measuring long-term follow-up
in Friedreich ataxia. As a result of the different variables in design
and implementation in the included studies, which we assessed as
a potential risk of bias, we downgraded the quality of the evidence
for change in the ICARS score.
The evidence published in the included studies was direct. There
was significant heterogeneity in the study participants and consid-
erable inconsistency in the results for change in the cardiac mea-
sure, interventricular thickness, and as a result we found it neces-
sary to downgrade the quality of evidence for these outcomes. As
there were so few participants (N = 72), only two of whom expe-
rienced events, we downgraded the results due to imprecision for
the outcomes mild adverse events and severe adverse events. The
larger of the two unpublished studies appeared likely to strengthen
a finding of no effect for idebenone on both neurological (the
ICARS and FARS) and “anatomical and functional cardiological
parameters” (Weidemann 2012). On this basis, we chose not to
downgrade the evidence for publication bias, although these re-
sults were mentioned in a press release and not available for veri-
fication.
Potential biases in the review process
There may be some potential for bias in this review process as
there were changes to the protocol. These included additions and
deletions to the outcomes, as reported in Differences between
protocol and review. None of these changes were made as a result
of the findings of the included studies but rather to improve the
structure of the review. We are confident that we have identified all
clinically relevant trials, as we conducted a comprehensive search
of all published literature and clinical trials registers for potentially
relevant clinical trials and three of the review authors regularly
attend international conferences on Friedrieich ataxia.
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As the review includes data fromonly two small RCTs, it is possible
that our methods have not detected all rare and serious adverse
events. This review defines severe adverse events as those leading to
withdrawal, which has been adequate for describing serious adverse
events in currently included trials. We will widen our definition to
also include adverse events that are fatal, life threatening, or require
prolonged hospitalisation in future updates, if they are measured
in newly included studies.
Agreements and disagreements with other
studies or reviews
Some open-label trials of idebenone found an improvement in
cardiacmeasures (Buyse 2003;Mariotti 2003; Pineda 2008; Ribai
2007; Rustin 1999), but others, Lynch 2010, a six-month RCT
and Artuch 2002, did not. Lynch 2010 found that idebenone at
similar or higher doses than those that were used in Mariotti 2003
did not improve ejection fraction over a period of six months,
in participants with Friedreich ataxia. As mentioned previously,
we did not include Lynch 2010 in the review owing to its short
duration.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low-quality evidence from the two small, published, included ran-
domised controlled trials neither supported nor refuted an effect
from antioxidants (idebenone, or a combination of coenzymeQ10
and vitamin E) on the neurological status of people with Friedre-
ich ataxia, measured with a validated neurological rating scale.
A large unpublished study of idebenone that reportedly failed to
meet neurological endpoints, and a trial of pioglitazone remain
unpublished, but on publication will very likely influence qual-
ity assessments and conclusions. Cardiac changes were based on
low- and very low-quality evidence of uncertain clinical signifi-
cance. According to low-quality evidence, serious and non-serious
adverse events were rare in both antioxidant and placebo groups.
Other classes of agents have not been tested in clinical trials eligi-
ble for inclusion in this review.
Implications for research
Publication of data from unpublished trials is highly desirable,
as important data may be missing from this review. The clinical
importance of observed cardiac changes with antioxidants might
warrant further investigation. Future studies might also investi-
gate whether pharmacological interventions such as antioxidants
have any complementary or adjunctive role in the treatment of
Friedreich ataxia.
Friedreich ataxia is a rare, slowly progressive disorder. Researchers
have not yet defined a suitable clinical marker or biomarker to
assess disease progression. Clinical assessment becomes even more
difficult when the patient is wheelchair-dependent. In view of
these factors, and in order to evaluate the effects of other pharma-
cological treatments in Friedreich ataxia, we need large, placebo-
controlled RCTs of 12 months’ duration, using clinical scales that
are both valid and responsive to change
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cooper 2008
Methods Randomised, double-blind trial
Participants 50 people with Friedreich ataxia
Interventions High-dose or low-dose coenzyme Q10 or vitamin E
Outcomes Outcomes of relevance to this review:
• Primary - change in ICARS score after 12 months’ treatment
• Secondary - change in IVS thickness
Funding Pharma Nord provided vitamin E, coenzyme Q10 and placebo tablets
Grant from Ataxia UK, Wellcome Trust and Medical Research Council
Conflicts of interest None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Statistician external to the study randomised patients
to give 2 groups of 24 and 26”
Allocation concealment (selection bias) Low risk “double blind was maintained until all evaluations
were complete at the 2 years time point”. Allocation
concealment not precisely stated, but external person-
nel were responsible for randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double blind was maintained until all evaluations
were complete at the 2 years time point”. Report states
that ’placebo’ and active tables were “indistinguish-
able”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “double blind was maintained until all evaluations
were complete at the 2 years time point”
Incomplete outcome data (attrition bias)
Neuological outcome
Low risk 7 withdrawals: 6 withdrew within the first 6 months
and a further participant did not complete the final as-
sessment. 4 withdrawals were voluntary, 1 participant
with severe Friedreich ataxia was unable to continue
with the assessments, and 2 had adverse reactions (1
in the high dose group, 1 in the low dose group)
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Cooper 2008 (Continued)
Selective reporting (reporting bias) Low risk Reporting was selective in the published material but
we judge there to be a low risk of bias for this domain
following provision of additional data
Other bias Unclear risk The manuscript does not report what percentage of
each groupwere wheelchair-dependent and this could
have a significant effect on the results
Mariotti 2003
Methods Randomised, double-blind, placebo-controlled clinical trial
Participants 29 participants with Friedreich ataxia: 14 received idebenone, 15 received placebo; mean
age 26.2 years (range 20.8 to 31.8 years); mean duration of illness 15.1 years (range 10.
6 to 20.1)
Interventions 5 mg/kg idebenone three times daily for one year or identical placebo
Outcomes Outcomes of relevance to this review:
• Change in ICARS score
• Change in left ventricular mass as measured by echocardiography
Funding Supported by a grant from the Italian Ministry of Health. Takeda-Italy provided
idebenone and placebo
Conflicts of interest Not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization of patients, strati-
fied according to IVS thickness at baseline
(IVS = 12 to 14 mm, and > 14 mm) was
computer generated”
Comment: probably done
Allocation concealment (selection bias) Low risk Study author told review authors that out-
come assessorswere blinded toparticipants’
assignment until the end of the study. Not
described, but assessed as low risk because
of computer-generated randomisation, and
maintenance of blinding
24Pharmacological treatments for Friedreich ataxia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mariotti 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Idebenone 60 mg/capsule and
identical placebo capsules were prepack-
aged and provided by Takeda”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “were blind to patient assignment”
Incomplete outcome data (attrition bias)
Neuological outcome
Low risk Data on primary outcome sought and ob-
tained, 1 placebo assignee died from di-
abetic ketoacidosis 5 months after enrol-
ment
Selective reporting (reporting bias) Low risk Data for change in ICARS score were not
shown in the published report but were
supplied by the trial author
Other bias High risk The proportion of wheelchair-dependent
and non-wheelchair-dependent partici-
pants was significantly different in each
group. Seven of the fourteen partici-
pants were wheelchair-dependent in the
idebenone treated group. Eleven of the fif-
teen participants in the placebo group were
wheelchair-dependent
NCT00811681
Methods Randomised, double-blind, placebo-controlled clinical trial
Participants 40 participants with genetically-confirmed Friedreich ataxia with GAA repeat length of
the shorter allele of frataxin gene > 300
Interventions Pioglitazone and placebo
Outcomes Outcomes of relevance to this review:
• Change in ataxia rating scales as measured by ICARS and FARS every 6 months
over a 2-year period.
• Change in cardiac parameters as measured by electrocardiography, 24-hour
Holter, echocardiography with tissue doppler or cardiac magnetic resonance
spectroscope
• Change in quality of life scale measured by the Short Form 36 (SF-36) health
survey after 12 months of treatment
Funding Assistance Publique - Hôpitaux de Paris
Conflicts of interest Not stated in clinical trials registration
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NCT00811681 (Continued)
Notes French national multi-centre study, final data collection March 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Clinicial trials registration reported study
design “allocation: Randomized”
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinicial trial registration reported study
design “Masking: Double blind (Subject,
Investigator)”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk Study completed March 2013, no publica-
tion to date (December 2015)
Other bias Unclear risk No information
Weidemann 2012
Methods Randomised, double-blind, placebo-controlled clinical trial
Participants 232 enrolled participants with genetically-confirmed Friedreich ataxia
Interventions Placebo or weight-adjusted daily doses of idebenone as follows (for participants with ≤
and >45 kg body weight):
Low dose: 180 mg or 360 mg
Mid dose: 450 mg or 900 mg
High dose: 1350 mg or 2250 mg
Outcomes Outcomes of relevance to this review, measured from baseline to week 52:
• change in ataxia rating scale as measured by ICARS
• change in FARS scores
• proportion of improving on ICARS “by a clinically relevant margin” (of 2.5
ICARS points)
In participants presenting with cardiac involvement:
• proportion improving on LV peak systolic strain rate or showing a reduction in
LVM index with no worsening in strain rate
• change in peak systolic strain rate
• change in peak workload as assessed by a modified exercise test
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Weidemann 2012 (Continued)
Funding Santhera Pharmaceuticals
Conflicts of interest Unpublished - not reported
Notes ClinicalTrials.gov identifier: NCT00905268
Europeanmulti-centre studywith 13 centres in Belgium, France, Germany,Netherlands,
and UK. Study completion date January 2010. Santhera, the pharmaceutical company
organising the study issued a statement in May 2010 stating that “the study failed to
reach its primary endpoint”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) High risk Study completed Spring 2010, no publica-
tion to date (December 2015)
Other bias Unclear risk No information
ICARS: International Co-operative Ataxia Rating Scale; FARS: Friedreich Ataxia Rating Scale; IVS: interventricular septum; LVM: left
ventricular mass; LV: left ventricular
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Di Prospero 2007 Duration of RCT insufficient (6 months)
Lynch 2010 Duration of RCT insufficient (6 months)
Mariotti 2010 Duration of RCT insufficient (6 months)
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(Continued)
Pandolfo 2014 Duration of RCT insufficient (6 months)
Schöls 2005 Duration of RCT insufficient (4 months)
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D A T A A N D A N A L Y S E S
Comparison 1. Antioxidant versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ICARS score 2 72 Mean Difference (IV, Fixed, 95% CI) 0.79 [-1.97, 3.55]
2 Ejection fraction 1 28 Mean Difference (IV, Fixed, 95% CI) -0.21 [-5.55, 5.13]
3 Interventricular septal thickness 2 72 Mean Difference (IV, Random, 95% CI) -0.65 [0.00, 0.70]
4 Left ventricular mass 1 28 Mean Difference (IV, Fixed, 95% CI) -30.3 [-53.34, -7.26]
5 Mild adverse events 2 72 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Severe adverse events 2 72 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.00]
Analysis 1.1. Comparison 1 Antioxidant versus placebo, Outcome 1 ICARS score.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 1 ICARS score
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cooper 2008 22 -0.64 (4.59) 22 0 (5.57) 83.8 % -0.64 [ -3.66, 2.38 ]
Mariotti 2003 14 -0.8 (9.2) 14 -9 (9.3) 16.2 % 8.20 [ 1.35, 15.05 ]
Total (95% CI) 36 36 100.0 % 0.79 [ -1.97, 3.55 ]
Heterogeneity: Chi2 = 5.36, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours antioxidant Favours placebo
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Analysis 1.2. Comparison 1 Antioxidant versus placebo, Outcome 2 Ejection fraction.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 2 Ejection fraction
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Mariotti 2003 14 0.43 (8.52) 14 0.64 (5.6) 100.0 % -0.21 [ -5.55, 5.13 ]
Total (95% CI) 14 14 100.0 % -0.21 [ -5.55, 5.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours placebo Favours antioxidant
Analysis 1.3. Comparison 1 Antioxidant versus placebo, Outcome 3 Interventricular septal thickness.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 3 Interventricular septal thickness
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Mariotti 2003 14 -0.71 (1.63) 14 0.67 (1) 46.9 % -1.38 [ -2.38, -0.38 ]
Cooper 2008 22 0.27 (1.39) 22 0.27 (1.12) 53.1 % 0.0 [ -0.75, 0.75 ]
Total (95% CI) 36 36 100.0 % -0.65 [ -2.00, 0.70 ]
Heterogeneity: Tau2 = 0.75; Chi2 = 4.69, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours antioxidant Favours placebo
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Analysis 1.4. Comparison 1 Antioxidant versus placebo, Outcome 4 Left ventricular mass.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 4 Left ventricular mass
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
Mariotti 2003 14 -14 (32.75) 14 16.3 (29.37) 100.0 % -30.30 [ -53.34, -7.26 ]
Total (95% CI) 14 14 100.0 % -30.30 [ -53.34, -7.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours antioxidant Favours placebo
Analysis 1.5. Comparison 1 Antioxidant versus placebo, Outcome 5 Mild adverse events.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 5 Mild adverse events
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cooper 2008 0/22 0/22 Not estimable
Mariotti 2003 0/14 0/14 Not estimable
Total (95% CI) 36 36 Not estimable
Total events: 0 (Antioxidant), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antioxidant Favours placebo
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Analysis 1.6. Comparison 1 Antioxidant versus placebo, Outcome 6 Severe adverse events.
Review: Pharmacological treatments for Friedreich ataxia
Comparison: 1 Antioxidant versus placebo
Outcome: 6 Severe adverse events
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cooper 2008 1/22 1/22 100.0 % 1.00 [ 0.07, 15.00 ]
Mariotti 2003 0/14 0/14 Not estimable
Total (95% CI) 36 36 100.0 % 1.00 [ 0.07, 15.00 ]
Total events: 1 (Antioxidant), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours antioxidant Favours placebo
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS)
#1 friedreich NEAR ataxia* [REFERENCE] [STANDARD]
#2 freidreich NEAR ataxia* [REFERENCE] [STANDARD]
#3 #1 or #2 [REFERENCE] [STANDARD]
#4 idebenone or noben or “ascorbic acid” “vitamin C” or “vitamin E” or “vitamin A” [REFERENCE] [STANDARD]
#5 “alpha Tocopherol” or alphatocopherol [REFERENCE] [STANDARD]
#6 Selegiline or “Superoxide Dismutase” or Dehydroepiandrosterone or Glutathione or Urea or “Uric Acid” or Selenium or Erythro-
poietin [REFERENCE] [STANDARD]
#7 “Iron Chelating Agents” or “Chelation Therapy” or deferiprone or Pyridones or pioglitazone [REFERENCE] [STANDARD]
#8 MeSH DESCRIPTOR Antioxidants Explode All [REFERENCE] [STANDARD]
#9 MeSH DESCRIPTOR Therapeutics Explode All [REFERENCE] [STANDARD]
#10 n NEAR1 acetyl NEAR3 cysteine [REFERENCE] [STANDARD]
#11 n NEAR1 acetylcysteine [REFERENCE] [STANDARD]
#12 deprenyl or carotene or carotenoids or flavonoids or taurine [REFERENCE] [STANDARD]
#13 “recombinant human erythropoietin” [REFERENCE] [STANDARD]
#14 “iron chelat*” [REFERENCE] [STANDARD]
#15 deferiprone or pioglitazone or therapy or treatment [REFERENCE] [STANDARD]
#16 “Histone Deacetylase” NEAR1 Inhibitor* [REFERENCE] [STANDARD]
#17 deacetylase NEAR1 Inhibitor* NEAR1 histone [REFERENCE] [STANDARD]
#18 hdac NEAR1 inhibitor* [REFERENCE] [STANDARD]
#19 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 [REFERENCE] [STANDARD]
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#20 #3 and #19 [REFERENCE] [STANDARD]
#21 (#3 and #19) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. CENTRAL (CRSO) search strategy
Search run on Mon Feb 29 2016
#1 (Friedreich NEAR ataxia*):TI,AB,KY57
#2 (idebenone or noben or “ascorbic acid” “vitamin C” or “vitamin E” or “vitamin A”):TI,AB,KY 4474
#3 (“alpha Tocopherol” or alphatocopherol):TI,AB,KY 1989
#4 (Selegiline or “Superoxide Dismutase” or Dehydroepiandrosterone or Glutathione or Urea or “Uric Acid” or Selenium or Erythro-
poietin):TI,AB,KY 14263
#5 (“Iron Chelating Agents” or “Chelation Therapy” or deferiprone or Pyridones or pioglitazone):TI,AB,KY 1778
#6 MESH DESCRIPTOR Antioxidants EXPLODE ALL TREES 11256
#7 MESH DESCRIPTOR Therapeutics EXPLODE ALL TREES 238526
#8 n NEAR1 acetyl NEAR3 cysteine 191
#9 n NEAR1 acetylcysteine 845
#10 deprenyl or carotene or carotenoids or flavonoids or taurine 3101
#11 (“recombinant human erythropoietin”):TI,AB,KY 842
#12 (“iron chelat*”):TI,AB,KY 313
#13 (deferiprone or pioglitazone or therapy or treatment):TI,AB,KY 508710
#14 (“Histone Deacetylase” NEAR1 Inhibitor*):TI,AB,KY 74
#15 (deacetylase NEAR1 Inhibitor* NEAR1 histone):TI,AB,KY 1
#16 (hdac NEAR1 inhibitor*):TI,AB,KY 14
#17 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 566110
#18 #1 AND #17 46
#19 sr-neuromusc:cc 5822
#20 #18 not #19 18
Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to February Week 3 2016>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (406624)
2 controlled clinical trial.pt. (90068)
3 randomized.ab. (303867)
4 placebo.ab. (155146)
5 drug therapy.fs. (1821266)
6 randomly.ab. (215136)
7 trial.ab. (313195)
8 groups.ab. (1362139)
9 or/1-8 (3453304)
10 exp animals/ not humans.sh. (4189142)
11 9 not 10 (2940585)
12 Friedreich Ataxia/ (2246)
13 (friedreich adj5 ataxia).tw. (721)
14 12 or 13 (2423)
15 (idebenone or noben).mp. (405)
16 Ascorbic Acid/ or Vitamin E/ or Vitamin A/ (76994)
17 alpha-Tocopherol/ (4395)
18 Selegiline/ (2277)
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19 Acetylcysteine/ (10972)
20 Superoxide Dismutase/ (42033)
21 Dehydroepiandrosterone/ (8861)
22 Glutathione/ (48333)
23 Urea/ (39831)
24 Uric Acid/ (20792)
25 Selenium/ (17636)
26 Carotenoids/ (15664)
27 Flavonoids/ (31297)
28 Taurine/ (8687)
29 Erythropoietin/ (21625)
30 Iron Chelating Agents/ (5391)
31 Chelation Therapy/ (1227)
32 deferiprone.mp. (915)
33 Pyridones/ (5772)
34 pioglitazone.mp. (3895)
35 exp Antioxidants/ (379084)
36 exp Therapeutics/ (3610513)
37 (vitamin adj5 (a or c or e)).mp. (92827)
38 ascorbic acid.mp. (46493)
39 (alphatocopherol or alpha-tocopherol).mp. (13896)
40 (selegiline or deprenyl or superoxide dismutase or dehydroepiandrosterone or glutathione).mp. (170930)
41 ((n adj acetyl adj3 cysteine) or (n adj acetylcysteine)).mp. (13647)
42 (urea or uric acid or selenium or carotene or carotenoids or flavonoids or taurine).mp. (210103)
43 (recombinant human erythropoietin or iron chelat$ or deferiprone or pioglitazone).mp. (17259)
44 (therapy or treatment).tw. (3652967)
45 Histone Deacetylase Inhibitors/ (7162)
46 (histone deacetylase adj1 Inhibitor$).tw. (5172)
47 (deacetylase adj1 Inhibitor$ histone).tw. (33)
48 (hdac adj1 inhibitor$).tw. (3586)
49 or/15-48 (6513415)
50 14 and 49 (550)
51 Friedreich Ataxia/dt [Drug Therapy] (157)
52 11 and (50 or 51) (218)
53 remove duplicates from 52 (216)
Appendix 4. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2016 Week 09>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (46158)
2 double-blind procedure.sh. (126385)
3 single-blind procedure.sh. (21564)
4 randomized controlled trial.sh. (393423)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1223922)
6 trial.ti. (193286)
7 or/1-6 (1370827)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1446761)
9 animal/ or nonanimal/ or animal experiment/ (3498115)
10 9 not 8 (2901774)
11 7 not 10 (1261401)
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12 limit 11 to embase (1041826)
13 Friedreich Ataxia/ (3589)
14 (friedreich adj5 ataxia).tw. (984)
15 13 or 14 (3694)
16 (idebenone or noben).mp. (1211)
17 Ascorbic Acid/ or Vitamin D/ or Alpha Tocopherol/ (166246)
18 SELEGILINE/ (8761)
19 Acetylcysteine/ (27733)
20 Superoxide Dismutase/ (63090)
21 Prasterone/ (13044)
22 GLUTATHIONE/ (73101)
23 UREA/ (57055)
24 Uric Acid/ (30264)
25 SELENIUM/ (30785)
26 CAROTENE/ (2097)
27 Carotenoid/ (17745)
28 Flavonoid/ (38647)
29 TAURINE/ (11676)
30 Recombinant Erythropoietin/ (18331)
31 Iron Chelation/ (5247)
32 DEFERIPRONE/ (2466)
33 PIOGLITAZONE/ (14801)
34 exp Antioxidant/ (118651)
35 or/16-34 (579260)
36 15 and 35 (572)
37 (vitamin adj (a or c or e)).mp. (66264)
38 (ascorbic acid or selegiline or deprenyl superoxide dismutase or dehydroepiandrosterone).mp. (101221)
39 ((alpha adj tocopherol) or (n adj acetyl adj3 l adj3 cysteine) or (n adj acetylcysteine)).mp. (77957)
40 (glutathione or urea or uric acid or selenium or carotene or carotenoid$1 or flavonoid$1 or taurine).mp. (427286)
41 (recombinant human erythropoietin or iron chelat$ or deferiprone or pioglitazone or antioxidant$1 or (anti adj oxidant$1)).mp.
(255515)
42 (therapy or treatment).mp. (6748927)
43 histone deacetylase inhibitor/ (12403)
44 (histone deacetylase adj1 Inhibitor$).mp. (15381)
45 (deacetylase adj1 Inhibitor$ histone).mp. (59)
46 (hdac adj1 inhibitor$).mp. (6742)
47 or/16-46 (7313230)
48 15 and 47 (1178)
49 Friedreich ataxia/dt [Drug Therapy] (347)
50 12 and (48 or 49) (97)
51 remove duplicates from 50 (97)
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Appendix 5. CINAHL (EBSCOhost) search strategy
Monday, February 29, 2016 10:42:46 AM
S22 S18 and S21 90
S21 S19 or S20 247
S20 friedreich* ataxia 247
S19 (MH “Friedreich’s Ataxia”) 194
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 812,608
S17 ABAB design* 91
S16 TI random* or AB random* 166,706
S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) ) 331,594
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 118,835
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 43,606
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) ) 25,698
S11 PT (“clinical trial” or “systematic review”) 131,468
S10 (MH “Factorial Design”) 967
S9 (MH “Concurrent Prospective Studies”) or (MH “Prospective Studies”) 278,869
S8 (MH “Meta Analysis”) 24,148
S7 (MH “Solomon Four-Group Design”) or (MH “Static Group Comparison”) 49
S6 (MH “Quasi-Experimental Studies”) 7,730
S5 (MH “Placebos”) 9,644
S4 (MH “Double-Blind Studies”) or (MH “Triple-Blind Studies”) 33,107
S3 (MH “Clinical Trials+”) 196,275
S2 (MH “Crossover Design”) 13,598
S1 (MH“RandomAssignment”) or (MH“RandomSample”) or (MH“Simple RandomSample”) or (MH“StratifiedRandom Sample”)
or (MH “Systematic Random Sample”) 71,958
Appendix 6. ORPHANET search strategy
1. Simple Search: Friedreich’s ataxia by disease name
2 Result(s)
• Ataxia, Friedreich-like, with selective vitamin E deficiency
• Friedreich ataxia
Appendix 7. TRIP search strategy
Search Strategy for TRIP
1. Quick Search: Friedreich’s ataxia by Title [43 Records]
2. Quick Search: Friedreich ataxia by Title[53 Records]
3. Quick Search: Idebenone by Title [23 Records]
4. Quick Search: friedreich ataxia AND antioxidant treatment [11 Records]
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Appendix 8. Clinical Trials Registries
ClinicalTrials.gov
International Clinical Trials Registry Platform (ICTRP)
1 Simple search : Friedreich’s Ataxia by disease name
WH A T ’ S N E W
Last assessed as up-to-date: 29 February 2016.
Date Event Description
10 October 2016 Amended Revision to sentence in Background regarding action of deferiprone
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 4, 2009
Date Event Description
2 September 2016 Amended Correction to information about interferon gamma-1b
in the background
11 March 2015 New citation required and conclusions have changed Searches updated to 29 February 2016. Three addi-
tional included studies
11 March 2015 New search has been performed The text was revised throughout and ’Summary of find-
ings’ tables included
7 December 2011 New citation required but conclusions have not
changed
New search, no new studies included
4 October 2011 New search has been performed We updated the searches to 11 July 2011. Nonew stud-
ies were identified for inclusion. We included more de-
tail on ataxia rating scales and a PRISMA flow diagram
18 January 2010 Amended Figures in Table 1 corrected. Other minor changes.
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C O N T R I B U T I O N S O F A U T H O R S
Dr Mary Kearney, with the help of Prof Massimo Pandolfo, wrote the first draft of the protocol; Dr Richard Orrell and Dr Michael
Fahey edited the protocol. Dr Mary Kearney edited the final text, and all agreed to the final version submitted on 2 November 2008
and published in April 2009. Dr Mary Kearney and Dr Richard Orrell performed data extraction and analyses. Dr Mary Kearney wrote
the first draft of the review, and the other co-authors contributed to subsequent revisions for important intellectual content. Dr Mary
Kearney, Dr Richard Orrell, and Dr Michael Fahey inspected the list of clinical trials. Dr Mary Kearney wrote the draft for the updated
version of the review, Dr Ruth Brassington assisted with presenting data and creating ’Summary of findings’ tables, and all authors
contributed to revisions for important intellectual content.
D E C L A R A T I O N S O F I N T E R E S T
Dr Richard Orrell and Dr Mary Kearney have no conflicts of interest.
Professor Massimo Pandolfo was an investigator in the MICONOS (Santhera, idebenone) and LA-29 (Apopharma, deferiprone) trials,
for which his institution received funding. His institution has received a research grant from Repligen Corporation for testing novel
HDAC inhibitors in patients’ cells and in mouse models of Friedreich ataxia. He has received honoraria from Santhera and Apopharma.
He has received royalties fromAthenaDiagnostics for granting an exclusive license to commercially perform genetic testing for Friedreich
ataxia. None of the declared relationships have influenced this review in any way.
Dr Michael Fahey has served on a scientific advisory board and acted as a consultant for Actelion Pharmaceuticals Ltd and also received
funding for travel. He receives research support from NHMRC and the NIH (1R03HD058625-01, CI). He holds stock in Sigma
Pharmaceuticals and has given expert testimony on behalf of the Therapeutic Goods Administration.
Dr Ruth Brassington has no known financial or intellectual conflicts of interest. She is Managing Editor of Cochrane Neuromuscular,
of which The National Institute for Health Research (NIHR) is the largest single founder. A grant from the Motor Neurone Disease
Association also contributes to her salary.
S O U R C E S O F S U P P O R T
Internal sources
• Ruth Brassington, UK.
Salary from University College Hospitals London NHS Foundation Trust, which hosts Cochrane Neuromuscular
External sources
• Ruth Brassington, UK.
Salary paid from a National Institute of Health Research (NIHR) Cochrane Infrastructure Support grant and a small grant from the
Motor Neurone Disease Association to Cochrane Neuromuscular
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Three of the four authors inspected the list of potentially relevant studies.
We did not search the NORD databasefor this or the previous update.
As searching AMED, LILACS, and PEDRO produced no useful results, we did not search these databases for the 2015 update.
We included a ‘Summary of findings’ table. We added a PRISMA flow chart in the 2012 update to show the study selection process.
In the 2015 update, we changed the primary outcome to
Change in validated Friedreich ataxia neurological score such as:
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• ataxia rating score, Scale for the Assessment and Rating of Ataxia (SARA) after 12 months treatment
• ataxia rating score, Friedreich Ataxia Rating Scale (FARS) after 12 months treatment
• ataxia rating score, International Cooperative Ataxia Rating Scale (ICARS) after 12 months treatment
and we changed the secondary outcomes:
1. Change in cardiac measures, ejection fraction, interventricular septal wall thickness (IVSTd), and left ventricular mass (LVM),
after 12 months treatment as measured by cardiac magnetic resonance imaging (cMRI):
2. Change in cardiac measures, ejection fraction, IVSTd, LVM after 12 months’ treatment as measured by echocardiogram.
Change in authorship: addition of Dr Ruth Brassington.
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Medical Subject Headings (MeSH)
Antioxidants [adverse effects; ∗therapeutic use]; Friedreich Ataxia [∗drug therapy]; Heart [drug effects]; Hypertrophy, Left Ventricular
[diagnostic imaging; drug therapy]; Randomized Controlled Trials as Topic; Rare Diseases [drug therapy]; Ubiquinone [adverse effects;
∗analogs & derivatives; therapeutic use]; Ultrasonography; Vitamin E [adverse effects; ∗therapeutic use]
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